What if you invested $1000 in EW on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Edwards Lifesciences Corporation has delivered an average annual return of 22.2%. The stock peaked in 2014 with a massive +93.2% gain, while investors faced a downturn in 2022 (-41.9%). Overall, the stock finished in the green 15 times out of 20 years.
Avg Return
+22.2%
Win Rate
75%
15W - 5L
Best
+93.2%
2014
Worst
-41.9%
2022
Performance Consistency
About Edwards Lifesciences Corporation
Visit Website ↗Edwards Lifesciences Corporation is the global leader in patient-focused innovations for structural heart disease and critical care monitoring. The company partners with clinicians to develop innovative technologies in the areas of structural heart disease, including transcatheter aortic heart valve replacement (TAVR), and critical care, focusing on advanced hemodynamic monitoring. Edwards' products are used to treat patients with heart valve diseases and to monitor patients in acute care settings globally.
Key Business Segments
Transcatheter Aortic Valve Replacement (TAVR)
Develops and manufactures devices for the minimally invasive replacement of the aortic heart valve.
Surgical Structural Heart
Offers a range of products for the surgical repair and replacement of heart valves.
Critical Care
Provides advanced hemodynamic monitoring solutions used to measure a patient's cardiovascular performance in critical care settings.
Key Innovations
- ✓Pioneered and continues to lead the development of transcatheter heart valve therapies, offering less invasive treatment options for patients with heart valve disease.
- ✓Introduced advanced hemodynamic monitoring technologies that provide clinicians with critical real-time patient data to guide treatment decisions.
Historical Milestones
Miles Edwards and Albert Starr create the first successful artificial heart valve, founding Edwards Laboratories.
Edwards Lifesciences spins off from Baxter International and becomes an independent public company.
Receives CE Mark for its first transcatheter aortic valve, marking a major breakthrough in structural heart therapy.